Keywords: GlaxoSmithKline, H1N1 vaccine, FDA approval, WHO, Relenza
GlaxoSmithKline’s pandemic H1N1 vaccine cleared by US FDA; firm donates 50M doses to WHO
Article | 12 November 2009
The US Food and Drug Administration has cleared UK drug giant GlaxoSmithKline’s supplemental Biologics License Application for its unadjuvanted ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
